Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07421167 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
NCT07421167 is a Phase 2 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 164 participants.
The verdict
NCT07421167, a Phase 2 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianalumab.
Interventions
- BIOLOGICAL ianalumab
- DRUG thrombopoietin receptor agonist (TPO-RA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2026-06-29 |
| Est. Completion | 2030-08-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07421167
The ClinicalTrials.gov registry entry for NCT07421167 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ianalumab is the first listed.
NCT07421167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07421167 about?
NCT07421167 is a clinical study titled "A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)". The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatmen...
What is the current status of trial NCT07421167?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2026-06-29. Estimated completion is 2030-08-08.
What interventions are being tested in trial NCT07421167?
The interventions under investigation include: ianalumab (BIOLOGICAL), thrombopoietin receptor agonist (TPO-RA) (DRUG).
Who is sponsoring clinical trial NCT07421167?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.